A 12-week home-based exercise program with nutritional guidance is associated with improved functional capacity in chronic liver disease.

Clin Nutr ESPENAug 29, 2026 (epub)
Clinical ResearchGastroenterology

Shinji Unome, Takao Miwa, Yoshihiko Atago et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective clinical trial evaluated a 12-week home-based exercise program with nutritional guidance in 46 patients with chronic liver disease (CLD). The program led to significant improvements in functional capacity, including a 33 m increase in the 6-min walking test. Most participants completed the intervention safely, with no serious adverse events reported.

Key findings

  • Participants showed a 33 m improvement in the 6-min walking test at week 12.
  • The Liver Frailty Index decreased by 0.14, indicating improved functional capacity.
  • Body weight-normalized knee extensor strength increased by 0.03.

Why it matters

Improving functional capacity in patients with chronic liver disease can enhance quality of life and potentially reduce healthcare utilization. Structured exercise programs may be an effective intervention in routine hepatology care.

Source

PubMed · PMID 42668018

Published in Clin Nutr ESPEN. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.